Compare SPT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPT | CCCC |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.7M | 404.7M |
| IPO Year | 2019 | 2020 |
| Metric | SPT | CCCC |
|---|---|---|
| Price | $8.24 | $4.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $11.75 | ★ $12.20 |
| AVG Volume (30 Days) | 1.4M | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.11 | 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $457,547,000.00 | $35,947,000.00 |
| Revenue This Year | $8.86 | N/A |
| Revenue Next Year | $8.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.72 | 1.02 |
| 52 Week Low | $4.92 | $1.69 |
| 52 Week High | $19.51 | $5.17 |
| Indicator | SPT | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 63.82 | 49.47 |
| Support Level | $5.97 | $2.10 |
| Resistance Level | $8.31 | $4.60 |
| Average True Range (ATR) | 0.46 | 0.41 |
| MACD | 0.10 | -0.05 |
| Stochastic Oscillator | 83.21 | 22.84 |
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.